Interestingly, it is less clear if TP53 status dictates the response to other DNA-damaging chemotherapies used for the treatment of colorectal cancer such as oxaliplatin and irinotecan that could indicate intrinsic differences in the p53 response between these chemotherapeutic agents20, 21. This evidence concerns the gene TP53 and colorectal cancer.